Purpose: Generation of antigen-specific T cells from patients with cancer employs large
numbers of peripheral blood cells and/or tumor-infiltrating cells to generate antigen …

Antigen-presenting cells expand antigen-specific T cells ex vivo and in vivo for tumor
immunotherapy, but are time-consuming to generate and, as live cells, raise biosafety …

The development of effective antitumor immune responses is normally constrained by low-
avidity, tumor-specific CTLs that are unable to eradicate the tumor. Strategies to rescue …

A major factor hindering the exploration of adoptive immunotherapy in preclinical settings is
the limited availability of tumor-reactive human T cells. Here we developed a humanized …

Peptide-based vaccines are currently being tested for their ability to induce or augment
tumor antigen (Ag)-specific CD8+ T-cell responses in cancer patients. Here we report that …

Induction of cytotoxic CD8 T-cell responses is enhanced by the exclusive presentation of
antigen through dendritic cells, and by innate stimuli, such as toll-like receptor ligands. On …

Tumor antigens that might serve as potential targets for adoptive T-cell therapy have been
defined in different tumor entities, especially in malignant melanoma. To generate conditions …

Exciting developments in cancer nanomedicine include the engineering of nanocarriers to
deliver drugs locally to tumors, increasing efficacy and reducing off-target toxicity associated …

Several sources of evidence suggest that tumor-specific T cells have the potential to control
melanoma tumors. Current active and adoptive therapeutic approaches to elicit such T cells …

Adoptive immunotherapy for treatment of cancers and infectious diseases is often hampered
by a high degree of variability in the final T cell product and in the limited in vivo function and …